PIPELINE

Nippon Shinyaku Co., Ltd. has been developing compounds in several therapeutic fields, including hematologic malignancies and intractable/orphan diseases, in Japan and China. NS Pharma, Inc. has been developing NS-018 (for myelofibrosis) and NS-065/NCNP-01 (for Duchenne muscular dystrophy) on behalf of Nippon Shinyaku Co., Ltd. The safety and efficacy of the product candidates have not been established by the FDA.

STAGE

CODE

FIELD

TARGET
INDICATION

ORIGIN

DEVELOPMENT

MECHANISM
OF ACTION

US: Phase I/II

NS-018

Hematologic
malignancies

Myelofibrosis

Nippon
Shinyaku

NS Pharma

Selective JAK2
inhibition

STAGE

CODE

FIELD

TARGET
INDICATION

ORIGIN

DEVELOPMENT

MECHANISM
OF ACTION

US: Phase III

NS 065/
NCNP-01
(viltolarsen)

Neurology

Duchenne
muscular
dystrophy

Nippon
Shinyaku,
NCNP

NS Pharma

Exon 53
skipping

NCNP=National Center of Neurology and Psychiatry.